SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
TapImmune Inc. Licenses HER2/neu Antigen Technology from Mayo Clinic for Incorporation Into a Vaccine to Treat HER2/neu Breast Cancer